Is NVS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

5,193 people get NVS articles and Market Currents by email alert.

Get email alerts on NVS »

HEADLINES:

Regeneron Shareholders Watching Optina Trial Closely
Tom Welch • Wed, May 22 • 5 Comments
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Peter Geschek • Wed, May 22 • 3 Comments
Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industry
Jon Crowley • Wed, May 22
Will Influenza A H7N9 Generate Opportunities For Pharma?
Jean-Christophe Larsimont • Tue, May 21 • 5 Comments
Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock
Emerging Equities • Wed, May 15
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Is Johnson & Johnson Heading Off The Patent Cliff?
Being Unordinary • Mon, May 13 • 7 Comments
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Companies Fighting Against Prostate Cancer
Equity Options Guru • Thu, May 9 • 10 Comments
3 Bio Companies Facing The Patent Cliff
Emerging Equities • Tue, May 7 • 1 Comment
Imminent Catalysts For Small Pharmaceuticals
Chemistfrog • Tue, May 7 • 9 Comments
After AbbVie's Humira: What Next?
Peter Geschek • Mon, May 6 • 1 Comment
Ophthalmology: A Niche Where Innovation Pays
Richard Richter • Mon, May 6 • 1 Comment
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
My Q2 Dividend Growth Watch List
Bob Wells • Fri, May 3 • 91 Comments
Stagflationary, Muddling, Sideways Economy And Market
Grey Owl Capital • Thu, May 2
Dividend Champions For May 2013
David Fish • Wed, May 1 • 41 Comments
Swinging For The Fences With Advanced Cell Technology
Michael J. Ray • Wed, May 1 • 56 Comments
A Tale Of Three Pharmaceuticals: Getting Exciting In 2013
Chemistfrog • Mon, Apr 29 • 18 Comments

To learn more about Seeking Alpha Pro, click here.

Novartis AG's New Medicine Approval Looks Interesting
StockBaller • Mon, Apr 22 • 1 Comment
Novartis Loses The Glivec Patent Fight In India
Derek Lowe • Mon, Apr 1 • 3 Comments
Novartis' Patent Denial
Profit Fan • Mon, Apr 1 • 1 Comment
3 Reasons To Buy This Leading Drug Stock Right Now
StreetAuthority • Fri, Mar 22 • 2 Comments
Will The Flu Vaccine Race Send Novartis Higher?
IncomeHunter • Thu, Feb 7 • 4 Comments
Novartis A Buy Thanks To Its Slow And Steady Dividend Growth
Jeroen Jongbloed • Thu, Feb 7 • 4 Comments
Novartis Improves Its Oncology Pipeline With Cutting Edge Technology
Brian L. Wilson • Thu, Jan 10 • 2 Comments
Buy Novartis For A Safe Dividend Yield
Horizon Investments • Fri, Dec 21, 2012 • 11 Comments
Novartis Moving Forward In Generics
Peter Pham • Mon, Dec 3, 2012
Buy Novartis: A Dividend Gem In The Pharmaceutical Industry
Qineqt • Tue, Nov 27, 2012 • 7 Comments
AHA - 2 Hits And Several Misses With Novartis' Serelaxin
EP Vantage • Wed, Nov 7, 2012
Novartis AG: Establish Long-Term Positions With 6.23% Discount Through Options
Nick Chiu • Mon, Oct 29, 2012
3 Reasons Novartis Creates Long-Term Opportunity
ValueMax • Wed, Oct 17, 2012 • 2 Comments
Novartis: Breaking Conglomerate Structure Could Unlock 50-60% Shareholder Returns
Pharma Intelligence • Wed, Oct 10, 2012 • 8 Comments
New Competition Could Drive Novartis Shares Down
Troy Bayer • Sun, Sep 23, 2012 • 2 Comments
Consider These Big Pharma Stocks Instead Of Novartis
Mel Daris • Tue, Sep 11, 2012 • 2 Comments
Buy Novartis: Dividend Gem Has Strong Product Portfolio, Growth Opportunities, High Margins
Qineqt • Wed, Aug 29, 2012 • 2 Comments
Novartis: New Drugs Will Lead Stock Higher By 2013
Cris Frangold • Mon, Aug 27, 2012 • 1 Comment
3 New Reasons To Buy Novartis Now
IncomeHunter • Mon, Aug 20, 2012 • 2 Comments
Novartis Well Positioned, But Will It Deliver?
Shankar N • Thu, Aug 2, 2012 • 3 Comments

Regeneron Shareholders Watching Optina Trial Closely
Tom Welch • Wed, May 22 • 5 Comments
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Peter Geschek • Wed, May 22 • 3 Comments
Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industry
Jon Crowley • Wed, May 22
Will Influenza A H7N9 Generate Opportunities For Pharma?
Jean-Christophe Larsimont • Tue, May 21 • 5 Comments
Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock
Emerging Equities • Wed, May 15
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Is Johnson & Johnson Heading Off The Patent Cliff?
Being Unordinary • Mon, May 13 • 7 Comments
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Companies Fighting Against Prostate Cancer
Equity Options Guru • Thu, May 9 • 10 Comments
3 Bio Companies Facing The Patent Cliff
Emerging Equities • Tue, May 7 • 1 Comment
Imminent Catalysts For Small Pharmaceuticals
Chemistfrog • Tue, May 7 • 9 Comments
After AbbVie's Humira: What Next?
Peter Geschek • Mon, May 6 • 1 Comment
Ophthalmology: A Niche Where Innovation Pays
Richard Richter • Mon, May 6 • 1 Comment
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
My Q2 Dividend Growth Watch List
Bob Wells • Fri, May 3 • 91 Comments
Stagflationary, Muddling, Sideways Economy And Market
Grey Owl Capital • Thu, May 2
Dividend Champions For May 2013
David Fish • Wed, May 1 • 41 Comments
Swinging For The Fences With Advanced Cell Technology
Michael J. Ray • Wed, May 1 • 56 Comments
A Tale Of Three Pharmaceuticals: Getting Exciting In 2013
Chemistfrog • Mon, Apr 29 • 18 Comments

Novartis' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 24
Novartis' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Jan 23
Novartis AG Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012
Novartis AG Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Jul 19, 2012
Novartis AG's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, Apr 24, 2012 • 1 Comment
Novartis AG's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Jan 25, 2012
Novartis AG's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Tue, Oct 25, 2011
Novartis AG's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Jul 19, 2011
Novartis CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Jan 27, 2011
Novartis 2009 Annual Conference Call Transcript
Tue, Jan 26, 2010
Novartis AG Q3 2007 Earnings Call Transcript
Thu, Oct 18, 2007 • 1 Comment
Novartis Q2 2007 Earnings Call Transcript
Tue, Jul 17, 2007

Early Movers: WMT, KSS, CSCO & More

at CNBC.com (Thu, 7:33AM)
Europe Shares Close Higher as Risk-On Rally Resumes

at CNBC.com (May 15, 2013)
Europe Closes Higher, Boosted by Novartis, BT

at CNBC.com (May 10, 2013)
U.S. Sues Novartis Over Drug Kickbacks

at Fox Business (Apr 26, 2013)
Dow Snaps 3-Day Rally; Telecoms Log Worst Day Since August 2011

at CNBC.com (Apr 24, 2013)
Futures Pare Gains After Durable Goods Orders

at CNBC.com (Apr 24, 2013)
Last Call: Market's Lucky Number Three

at CNBC.com (Apr 24, 2013)
Europe Markets: Europe stocks extend losses to third day

at MarketWatch.com (Apr 16, 2013)
Europe Markets: Europe stocks slide after China GDP; miners sink

at MarketWatch.com (Apr 15, 2013)
European Shares Close Off Highs Ahead of US Earnings

at CNBC.com (Apr 8, 2013)
Futures Turn Flat After ADP Employment Report

at CNBC.com (Apr 3, 2013)
Movers & Shakers: Monday movers: Apple kicks off new quarter in red

at MarketWatch.com (Apr 1, 2013)
Will Novartis decision impact U.S. drug prices?

at MarketWatch.com (Apr 1, 2013)
Novartis Loses Landmark India Patent Case

at Fox Business (Apr 1, 2013)
Indications: With stocks at record highs, ISM data to set tone

at MarketWatch.com (Apr 1, 2013)
Futures Hug Flatline Ahead of ISM Report

at CNBC.com (Apr 1, 2013)
Early Movers: WMT, PCS, AXP & More

at CNBC.com (Apr 1, 2013)
India rejects Novartis plea on cancer-drug patent

at MarketWatch.com (Apr 1, 2013)
Early Movers: MDT, ODP, OMX & More

at CNBC.com (Feb 19, 2013)
Denmark Faces Nokia Moment on $100 Billion Stock

at CNBC.com (Feb 1, 2013)

NVS vs. ETF Alternatives

Company Description

Currently, there's no company description for NVS.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: Switzerland

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 8:28 PM Actavis (ACT), which has rebuffed overtures from both Valeant (VRX) and more recently Mylan (MYL), may soon receive a bid from Novartis (NVS), WSJ says. "Intense price competition and fewer opportunities to cash in on patent expirations," are fueling a consolidation scramble in the generic-drug industry, the Journal notes, and ACT — which is also playing the role of acquirer in negotiations with Warner Chilcott (WCRX) — is at the center of the deal-making rumor mill. Comment! [Healthcare]
Tuesday, May 14, 10:23 AM Shares of Insmed (INSM +3.6%) pop after the company says the European Patent Office will grant a patent on ARIKACE, the company's clinical stage, inhaled treatment for cystic fibrosis patients with lung infections. In an exhaustive rundown, SA contributor Scott Matusow claims the drug is a superior alternative to Novartis' (NVS) TOBI for a number of reasons and also says INSM could capture a significant portion of the $424M (annually) market for CF pseudomonas lung infection treatments if top-line Phase III results (due mid-year) show promise. Comment! [Healthcare, On the Move, Quick Ideas]
Tuesday, May 7, 4:02 PM Endo Health (ENDP +0.8%) is set to finish in the green today, despite posting a mixed Q1. Net earnings swung to a profit amid fewer write-downs and other items, as well as a modest revenue increase on strong generic sales growth. Generic sales +23% at $178M, while branded-pharmaceutical sales declined 2% to $358M. Lidoderm sales dropped 11%, mostly owing to its supply agreement with Actavis (ACT). Sales of Opana ER slumped 31% as sales continue to lag following a disruption early last year resulting from the closing of a Novartis (NVS) plant. Comment! [Healthcare, Earnings]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, April 29, 10:28 AM Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription performance. According to data, the drug has already garnered nearly 8% of the multiple sclerosis market through the week ended April 19, with prescriptions up 120% over the prior week. By comparison, Novartis' (NVS) Gilenya saw a market share drop to 6%. RBC sees performance on track to meet quarterly sales expectations. Comment! [Healthcare, On the Move]
Monday, April 29, 8:25 AM Incyte (INCY) is set to receive a $25M milestone payment from Novartis (NVS) as a Phase II clinical trial for INC280 formally gets underway. NVS has exclusive development and commercialization rights to the compound. (PR) Comment! [Healthcare]
Friday, April 26, 6:56 PM Federal prosecutors have filed a second civil fraud suit against Novartis (NVS), accusing the drug giant of paying kickbacks and providing lavish dinners to doctors to encourage them to prescribe the company's brand-name drugs to treat hypertension and other ailments. Payments were disguised as honorariums for doctors to speak at educational programs, but the presentations were actually little more than social outings for doctors, including fishing trips off the Florida coast and outings to Hooters restaurants. 5 Comments [Healthcare]
Wednesday, April 24, 5:37 AM Novartis AG (NVS): Q1 EPS of $1.32 beats by $0.04. Revenue of $14B (+2% Y/Y) misses by $0.02B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 12:05 AM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Tuesday, April 23, 5:51 PM Manhattan AG sues Novartis (NVS) for offering pharmacies kickbacks to move patients to a Novartis drug used to prevent rejection of kidney transplants. "Novartis caused the public to pay tens of millions of dollars for kickback-tainted drugs that were dispensed by pharmacists who were in cahoots with the company. Novartis, as we allege, is a repeat offender, having settled healthcare fraud charges based on kickbacks less than three years ago," AG says. NVS -0.4% AH. (PR) Comment! [Breaking News, Healthcare]
Tuesday, April 23, 5:30 PM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Monday, April 22, 12:12 PM Biogen (BIIB +5.8%) rises after ICI analyst Mark Schoenebaum says the company's Tecfidera multiple sclerosis drug seems to be "crushing" its competitors. Following just a week on the market, Tecfidera's sales have achieved the same level that Novartis' (NVS) Gilenya reached after three months. However, Schoenebaum warns that it's still too early to make any definitive conclusions about Tecfidera. Comment! [Healthcare, On the Move]
Thursday, April 4, 2:37 PM ImmunoGen (IMGN +1.8%) says it's amended its multi-target agreement with Novartis (NVS -0.6%), which was originally entered into in October, 2010. As a result, IMGN is eligible to receive a $1M upfront fee and the opportunity to receive milestone payments potentially totaling approximately $200M or $238M, depending on the composition of any resultant products. 1 Comment [Healthcare, On the Move]
Tuesday, April 2, 4:12 PM Pfizer (PFE), Abbott Labs (ABT) and Novartis (NVS) are preparing to enter second-round bids for for Brazil's Ache Laboratorios Farmaceuticos in an auction that may value the group at over $5B. The bids are due in the second half of April, but divisions among certain families controlling the company still remain, fomenting uncertainty as to whether the deal will go ahead. Comment! [Healthcare, Global & FX]
Monday, April 1, 6:25 AM In a landmark decision, India's Supreme Court rejects Novartis' (NVS) bid for patent protection for its cancer drug Glivec, thus allowing the country's generic drugmakers to continue to sell copies at a lower price. Novartis India fell 1.8% on the Bombay exchange while generic manufacturer Natco Pharma surged 5.4%. 2 Comments [Healthcare]
Thursday, March 21, 8:59 AM Novartis' (NVS -1.1%) approved Gilenya treatment cut brain volume loss in multiple sclerosis patients by a third vs a comparator and a placebo and in three large Phase III trials. Brain volume loss is an important indicator of disease progression; data also shows that Gilenya consistently reduces relapse rates across disease activity. (PR) Comment! [Healthcare]

The Wall Street Transcript
Target Corporation ($TGT) and Novartis AG ($NVS) See a Decade of Dividend Growth- http://su.pr/2WdNba
May 14, 1:29 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Gare17
Check out my article : http://seekingalpha.com/p/137f5 $NVS $MRK $PFE $ZLCS
May 6, 1:08 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
$PSEC $AT and $BTE are the best yielding ex-dividend stocks for tomorrow - http://stks.co/p3Xx - I like $NVS $TWC and $UNP
Feb 25, 4:03 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ong Kang Wei
Dropped $WM from my dividend portfolio, and turned around and picked $DLR. Other recent changes: Addition of $NVS, $COP, $TGH
Feb 14, 8:28 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ocean Man
$IBM $220B market cap +4%, $GOOG $230B market cap +5%, $ISRG $20B market cap +8%, $NVS $160B market cap +2.4%. That's some weight on up.
Jan 23, 7:37 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Wednesday - $DDD, $SSYS, $HP, $ONVO.PK, $PFE, $UTHR, $VNDA, $NVS, $HEB http://bit.ly/cAHZ42
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
"Novartis ($NVS) says trial results back Tasigna drug." Another buy and hold and reinvest the dividends. http://bit.ly/12i6N8w
12/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

rasmy
NVS
10/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Mercy Jimenez
NVS flu vaccines temporarily halted in Italy; mayB NVS pps =more attractive http://reut.rs/Pr1bqh hat tip 2 Options Girl 4posting
10/24/12
Reply (1)

• !Report Abuse
View all 1 replies
driftking27: On calculating the possible divi income I receive £257, this means that I have only been taxed at 21% and NOT 35%.
Jan 26, 9:48 AM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Mercy Jimenez
NVS flu vaccines temporarily halted in Italy; mayB NVS pps =more attractive http://reut.rs/Pr1bqh hat tip 2 Options Girl 4posting
10/24/12
Reply (1)

• !Report Abuse
View all 1 replies
driftking27: On calculating the possible divi income I receive £257, this means that I have only been taxed at 21% and NOT 35%.
Jan 26, 9:48 AM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them
8/28/12
Reply (1)

• !Report Abuse
View all 1 replies
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
10/25/12
• !Report Abuse
Add a reply...

140 characters

Jacob Wolinsky
Johnson & Johnson: Why Value Investors Should be Looking http://bit.ly/M6zDRh $JNJ $NVS $AZN $BMY $PFE $GS
7/4/12
Reply (1)

• !Report Abuse
View all 1 replies
DaLatin: Not me.Like the dividend,but, IMHO JNJ is a Law firm who produces dangerous products for profit. Ya want to kill buy PM & get the divvy
7/4/12
• !Report Abuse
Add a reply...

140 characters

daisymae
CAT,UTX,ACM,DVS,NVS,SLB.
1/28/11
Reply (4)

• !Report Abuse
View all 4 replies
daisymae: daisymae says coal will be in demand in China...oher than that Nat. Gas is our future
6/17/12
• !Report Abuse
daisymae: AGNC gives off the best dividend...Mortgage REIT
6/21/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Best Dividend Paying Stock List April 2012 http://stks.co/3APf + $ABT $ARLP $BHP $CVX $CHL $GRMN $NVS $PEP $SSL $SCCO $STO $STRA $VALE $YPF
4/1/12
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: ARLP dipped last week, great entry price right now.
4/1/12
• !Report Abuse
Caiman Valores: YPF won't be paying a dividend, likely to be nationalized by Argentine government, find out more in my article http://bit.ly/ICs5GM
4/12/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Sold NVS for a 4% gain (including dividend) in 5 weeks. That was a dividend recovery play (annual payer).
3/19/12
Reply (4)

• !Report Abuse
View all 4 replies
shvartz: I bought at about 57. Adding the div to today's price gets about 58. And that is without tax, so for me there very little gain.
3/19/12
• !Report Abuse
Ocean Man: I bought some at 54.80 and sold at 57.40 pre-div, and I bought some at 55.80 which I sold today.
3/19/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology
3/5/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.
3/5/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Took some juicy profits on 1/4 to 1/2 of large positions in SM, CRZO, and NVS. Will take the div on the rest of NVS. CRZO reports Tuesday.
2/23/12
Reply (1)

• !Report Abuse
View all 1 replies
Hillbilly Stock Star: Me too! $$$
2/23/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Took some profits on CRK after a 9% up-move today, and added to NVS. My top play for the next 2 weeks is NVS on any weakness.
2/15/12
Reply (14)

• !Report Abuse
View all 14 replies
briandiplacido: disclaimer: I have 12 weeks experience doing this : )
2/21/12
• !Report Abuse
Ocean Man: Probably still worth a try at this price, only a few days left. I might buy some more, and will definitely buy any weakness.
2/21/12
• !Report Abuse
Add a reply...

140 characters

briandiplacido
NVS pulling back a bit.
2/17/12
Reply (3)

• !Report Abuse
View all 3 replies
briandiplacido: Marked my shares up a buck @ 57.74 and someone took it premarket. Look for better re-entry now.
2/21/12
• !Report Abuse
briandiplacido: Thanks OM.
2/21/12
• !Report Abuse
Add a reply...

140 characters

David Jackson
If you own dividend stocks like $INTC $JNJ $MSFT $NVS $DLN $DGS, note Vanguard's warning: http://seekingalpha.com/c/1fk0z
2/6/12
Reply (13)

• !Report Abuse
View all 13 replies
J. A. Saglimbeni: David, by the way a very good read by Vanguard...highly recommended
2/6/12
• !Report Abuse
Regarded Solutions: I use Fidelity, even like some funds, the business mod of these firms are geared for the bottom line. Not bad, just an opinion of mine
2/6/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Bought CLD, KGC, & NVS on the Fed news. CLD has a series of earnings beats, reports tomorrow, and is being added to S&P smcap 600 tomorrow.
1/25/12
Reply (2)

• !Report Abuse
View all 2 replies
Youngone91: ocean i bought kgc as well, for some reason kgc hesitated and i was able to pick it up at at 10.61
1/25/12
• !Report Abuse
Ocean Man: Nice job. I got it a bit higher so I could sell my GLD puts first (a $22,000 straddle takes precedence LOL!). But I'm still happy from 10.79
1/25/12
• !Report Abuse
Add a reply...

140 characters

Rocket Robin
Nice drop on NVS, will be interesting again soon :)
1/20/12
Reply (3)

• !Report Abuse
View all 3 replies
Rocket Robin: Got an article regarding this ?
1/21/12
• !Report Abuse
Ocean Man: Type their ticker into Yahoo - it's in their recent news.
1/22/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD
12/24/11
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I agree w/ NVS and STJ. I'd add SNY.
12/25/11
• !Report Abuse
mitrado: $MRK over 37.5 is quite a suicidal choice... it can go up to 50, but it can as easily fall back to 30... :-/
1/19/12
• !Report Abuse
Add a reply...

140 characters

NVS Novartis AG

NVS

Novartis AG